Sign In
Buy EVX
$41.34
-0.0600 (-0.145%)
At Close: Jul 13, 2026
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
09:30am, Sunday, 12'th Jul 2026
COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
08:00am, Wednesday, 01'st Jul 2026
COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present n
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
02:00am, Thursday, 11'th Jun 2026
COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
09:30am, Tuesday, 12'th May 2026
COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce
VanEck Announces Year-End Distributions for VanEck Equity ETFs
08:24pm, Friday, 19'th Dec 2025
NEW YORK--(BUSINESS WIRE)--VanEck announced today the 2025 annual distributions per share for its VanEck equity exchange-traded funds.
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - European Electric Metals Inc. (TSXV: EVX) (the "Company") is pleased to announce that it has entered into a mineral property purchase
Storm Exploration Enters Agreement to Sell the Miminiska Project
03:50pm, Monday, 01'st Dec 2025
VANCOUVER, BC / ACCESS Newswire / December 1, 2025 / Storm Exploration Inc. (TSXV:STRM) ("Storm" or the "Company") is pleased to announce that it has entered into a mineral property purchase agreement
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
05:10pm, Friday, 07'th Nov 2025
COPENHAGEN, Denmark, November 7, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data ex
European Electric Metals Announces Resumption of Trading
06:02pm, Wednesday, 22'nd Oct 2025
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - European Electric Metals Inc. (TSXV: EVX) (the "Company") announces that trading of the Company's common shares on the TSX Venture Ex
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
08:15am, Friday, 17'th Oct 2025
COPENHAGEN, Denmark, October 17, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new two-yea
COPENHAGEN, Denmark, October 13, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present a wide r
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting
09:00am, Friday, 03'rd Oct 2025
COPENHAGEN, Denmark, October 3, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present new data
COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-y
Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01
08:00am, Thursday, 22'nd May 2025
COPENHAGEN, Denmark, May 22, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has dosed the first patie
COPENHAGEN, Denmark, April 28, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new d
